Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma

British Journal of Haematology

Volumn 164, Issue 3, 2014, Pages 454-456

  Azoulay, David ^a,b   Lavie, David ^c   Horowitz, Netanel ^d   Suriu, Celia ^a,b   Gatt, Moshe E ^c   Akria, Luiza ^a,b   Perlman, Riki ^c   Braester, Andrei ^a,b   Ben Yehuda, Dina ^c  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Department of Haematology and BMT ^*  (Israel)

Author keywords

Bortezomib induced peripheral neuropathy; Brain derived neurotrophic factor; Multiple myeloma

Indexed keywords

BORTEZOMIB; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBRINOGEN RECEPTOR; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PHYCOERYTHRIN;

AGED; BLOOD SAMPLING; BRAIN DERIVED NEUROTROPHIC FACTOR BLOOD LEVEL; CELL LEVEL; CELLULAR SECRETION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY; BRAIN-DERIVED NEUROTROPHIC FACTOR; MULTIPLE MYELOMA;

AGED; BORONIC ACIDS; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES;

EID: 84892485112     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12624     Document Type: Letter

References (10)

1. Argyriou, A.A., Iconomou, G. & Kalofonos, H.P. (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593-1599.
2. Avcu, F., Ural, A.U., Cetin, T. & Nevruz, O. (2008) Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thrombosis Research, 121, 567-571.
3. Azoulay, D., Vachapova, V., Shihman, B., Miler, A. & Karni, A. (2005) Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. Journal of Neuroimmunology, 167, 215-218.
4. Broyl, A., Corthals, S.L., Jongen, J.L., van der Holt, B., Kuiper, R., de Knegt, Y., van Duin, M., el Jarari, L., Bertsch, U., Lokhorst, H.M., Durie, B.G., Goldschmidt, H. & Sonneveld, P. (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. The Lancet Oncology, 11, 1057-1065.
5. Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B. & Weinberger, D.R. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112, 257-269.
6. Farhadi, H.F., Mowla, S.J., Petrecca, K., Morris, S.J., Seidah, N.G. & Murphy, R.A. (2000) Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. Journal of Neuroscience, 20, 4059-4068.
7. Fujimura, H., Altar, C.A., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J., Sun, B. & Tandon, N.N. (2002) Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thrombosis and Haemostasis, 87, 728-734.
8. Hofer, M.M. & Barde, Y.A. (1988) Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature, 331, 261-262.
9. Richardson, P.G., Hideshima, T. & Anderson, K.C. (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control, 10, 361-369.
10. Zangari, M., Guerrero, J., Cavallo, F., Prasad, H.K., Esseltine, D. & Fink, L. (2008) Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica, 93, 953-954.